{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abacavir+%28ABC%29%2Flamivudine+%283TC%29", "query": { "intervention": "abacavir (ABC)/lamivudine (3TC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 108, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abacavir+%28ABC%29%2Flamivudine+%283TC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T10:31:11.305Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01622790", "title": "Evaluation of the Bioequivalence of a Combined Formulated Tablet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg", "type": "DRUG" }, { "name": "Dolutegravir 50 mg", "type": "DRUG" }, { "name": "abacavir 600 mg/lamivudine 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 66, "start_date": "2012-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-10-15", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01622790" }, { "nct_id": "NCT00005017", "title": "Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 1, "location_summary": "Research Triangle Park, North Carolina", "locations": [ { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005017" }, { "nct_id": "NCT00724711", "title": "Safety and Efficacy Study of Switching From Epzicom to Truvada", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)", "type": "DRUG" }, { "name": "abacavir (ABC)/lamivudine (3TC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2008-07", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 73, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00724711" }, { "nct_id": "NCT03631732", "title": "Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" }, { "name": "Third Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 496, "start_date": "2018-08-28", "completion_date": "2020-08-19", "has_results": true, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631732" }, { "nct_id": "NCT01499199", "title": "A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2012-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-02-25", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California • Providence, Rhode Island", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499199" }, { "nct_id": "NCT00046176", "title": "A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I", "HIV Infection" ], "interventions": [ { "name": "abacavir/lamivudine", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2002-08-26", "completion_date": "2004-05-17", "has_results": false, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 52, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046176" }, { "nct_id": "NCT00002183", "title": "A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 3, "location_summary": "San Diego, California • Denver, Colorado • Atlanta, Georgia", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002183" }, { "nct_id": "NCT01227824", "title": "A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I" ], "interventions": [ { "name": "GSK1349572 (dolutegravir)", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "GSK1349572 Placebo", "type": "OTHER" }, { "name": "ABC/3TC", "type": "OTHER" }, { "name": "TDF/FTC", "type": "OTHER" }, { "name": "raltegravir Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 828, "start_date": "2010-10-19", "completion_date": "2016-12-27", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227824" }, { "nct_id": "NCT00000865", "title": "The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "13 Years", "sex": "ALL", "summary": "3 Months to 13 Years" }, "enrollment_count": 32, "start_date": null, "completion_date": "1998-04", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 7, "location_summary": "Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "The Bronx", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000865" }, { "nct_id": "NCT01440569", "title": "Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2011-09", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-10-07T10:31:11.305Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01440569" } ] }